logo

For the Inventor, By the Inventor

Ridgewood, NJ, United States of America

Nicholas Moore

This inventor holds 4 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignee: H. Lundbeck A/s. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas Moore. Retrieved from https://idiyas.com/inventor/nicholas-moore

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 28(Granted Patents)


Location History:

  • Delmar, NY (US) (2014)
  • Ridgewood, NJ (US) (2017 - 2023)

Company Filing History:

goldMedal4 out of 513 
 
H. Lundbeck A/s
 patents

Years Active: 2014-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 11628166 - Therapeutic uses of compounds having combined sert, 5-HT3 and 5-HT1a activity (2023-04-18),
2. 9744166 - [object Object] (2017-08-29),
3. 8722684 - 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment (2014-05-13),
4. 8664225 - 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition (2014-03-04),

Title: Innovations by Inventor Nicholas Moore

Introduction

Nicholas Moore is a notable inventor based in Ridgewood, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. His work focuses on therapeutic uses of compounds that have combined activity, which has the potential to impact various medical treatments.

Latest Patents

Among his latest patents, one notable invention is related to the therapeutic uses of compounds having combined sert, 5-HT3, and 5-HT1a activity. This patent outlines new pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof. This innovative approach aims to enhance the efficacy of treatments in the pharmaceutical industry.

Career Highlights

Throughout his career, Nicholas Moore has worked with prominent companies such as H. Lundbeck A/S and Takeda Pharmaceuticals U.S.A., Inc. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in pharmaceutical research and development.

Collaborations

Some of his notable coworkers include Tine Bryan Stensbol and Marianne Dragheim. Their collaborative efforts have likely played a role in the successful development of his patented innovations.

Conclusion

Nicholas Moore's contributions to the pharmaceutical field through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new therapeutic solutions in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…